GFAPδ/GFAPα ratio directs astrocytoma gene expression towards a more malignant profile
Metrics: PDF 337 views | HTML 687 views | ?
Oscar M.J.A. Stassen1,2,*, Emma J. van Bodegraven3,*, Fabrizio Giuliani4, Martina Moeton1, Regina Kanski1, Jacqueline A. Sluijs3, Miriam E. van Strien3, Willem Kamphuis1, Pierre A.J. Robe4 and Elly M. Hol1,3,5
1Netherlands Institute for Neuroscience, an Institute of The Royal Netherlands Academy of Arts and Sciences, 1105 BA Amsterdam, The Netherlands
2Soft Tissue Engineering and Mechanobiology, Eindhoven University of Technology, 5612 AZ Eindhoven, The Netherlands
3Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, 3584 CG Utrecht, The Netherlands
4Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, 3584 CG Utrecht, The Netherlands
5Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, 1098 XH Amsterdam, The Netherlands
*These authors have contributed equally to this work
Elly M. Hol, email: firstname.lastname@example.org
Keywords: GFAP-isoforms, astrocytoma, transcriptomics, glioma, intermediate filaments
Received: April 07, 2017 Accepted: July 25, 2017 Published: October 04, 2017
Astrocytomas are the most common malignant brain tumours and are to date incurable. It is unclear how astrocytomas progress into higher malignant grades. The intermediate filament cytoskeleton is emerging as an important regulator of malignancy in several tumours. The majority of the astrocytomas express the intermediate filament protein Glial Fibrillary Acidic Protein (GFAP). Several GFAP splice variants have been identified and the main variants expressed in human astrocytoma are the GFAPα and GFAPδ isoforms. Here we show a significant downregulation of GFAPα in grade IV astrocytoma compared to grade II and III, resulting in an increased GFAPδ/α ratio. Mimicking this increase in GFAPδ/α ratio in astrocytoma cell lines and comparing the subsequent transcriptomic changes with the changes in the patient tumours, we have identified a set of GFAPδ/α ratio-regulated high-malignant and low-malignant genes. These genes are involved in cell proliferation and protein phosphorylation, and their expression correlated with patient survival. We additionally show that changing the ratio of GFAPδ/α, by targeting GFAP expression, affected expression of high-malignant genes. Our data imply that regulating GFAP expression and splicing are novel therapeutic targets that need to be considered as a treatment for astrocytoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.